Pharmaceutical companies have struggled to package GLP-1 agonists and other peptide-based drugs into pill form because peptides, chains of amino acids that are the building blocks of protein ...

giving rise to peptides such as the well-known metabolic regulator glucagon-like peptide 1 (GLP-1). To identify new peptides with potential pharmacological activity, the authors generated a ...

The development trend of glucagon-like peptide (GLP)-1 class obesity treatments is shifting from injectables to oral medications, prompting a rapid move to strengthen production capacity for ...

Supermarkets are selling more eggs. Gyms are getting rid of cardio machines to make more room for free weights. And cosmetic clinics are seeing a lot of “Ozempic face”. It’s estimated about ...

These body problems are not a side effect of the medication – glucagon-like peptide-1 receptor agonists, or GLP-1s – but a result of massive, rapid weight loss. While fat tissues shrink away ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for the treatment of type 2 diabetes mellitus and obesity, offer a novel, multilayered mechanism for intervention in ...

We speak with Rousselot’s principal scientist, Elhadji Dioum, about the company’s Nextida.GC collagen peptide product, which is designed to interact with GLP-1 and other weight loss medications. We ...

Pharmaceutical companies have struggled to package GLP-1 agonists and other peptide-based drugs into pill form because peptides, chains of amino acids that are the building blocks of protein, are ...

A study published in Current Neuropharmacology reveals a potential link between Glucagon-like Peptide-1 (GLP-1) receptor agonists, commonly used in drugs like Ozempic, and an increased risk of ...